Pharmacological Effects of Glycyrrhiza glabra L. as Antihepatitis and Hepatoprotective for Children

Abstract

Background: The incidence of hepatitis in children has grown from the normal number of hepatitis cases since January 2022, and it will continue to rise since the etiology and pathophysiology are unknown. This case is distinct from those caused by the hepatitis A, B, C, D, and E viruses. Glycyrrhiza glabra L. is a medicinal herb that has long been used in medicine to treat respiratory, digestive, and immune system problems, but it is also known to have an inhibitory impact on the virus. Coronavirus-associated acute respiratory syndrome, hepatitis, herpes simplex virus, influenza virus. Objective: This article will look at Glycyrrhiza glabra L.'s antihepatitis and hepatoprotective properties. Methods: The Pubmed, Sage Journal, and Sciencedirect databases were searched using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards and the keywords "Glycyrrhiza glabra for hepatitis." The inclusion and exclusion criteria were followed. Results: From the search results, 17 publications were discovered that explain how Glycyrrhiza glabra L. can operate as an antihepatitis agent through anti-inflammatory, antiapoptotic, and hepatoprotective mechanisms. Conclusion: Glycyrrhiza glabra L. can be used as an anti-hepatitis and hepatoprotective in children at doses ranging from 240-480mg/kg/day.